Reata Pharmaceuticals (NASDAQ:RETA – Free Report)‘s stock had its “reiterates” rating reiterated by equities researchers at 888 in a research report issued on Wednesday, Benzinga reports. RETA has been the subject of a number of other reports. Stifel Nicolaus lifted their price objective on Reata Pharmaceuticals from $105.00 to $115.00 and gave the company a […]
Reata Pharmaceuticals (NASDAQ:RETA – Free Report)‘s stock had its “reiterates” rating reiterated by analysts at 888 in a research note issued to investors on Wednesday, Benzinga reports. A number of other equities analysts also recently weighed in on the stock. SVB Securities raised shares of Reata Pharmaceuticals from a “market perform” rating to an “outperform” […]
888 reiterated their reiterates rating on shares of Reata Pharmaceuticals (NASDAQ:RETA – Free Report) in a research report released on Wednesday, Benzinga reports. RETA has been the subject of several other research reports. LADENBURG THALM/SH SH raised their price objective on shares of Reata Pharmaceuticals from $104.00 to $122.00 in a research note on Thursday. […]
Reata Pharmaceuticals (NASDAQ:RETA – Free Report) had its target price lifted by stock analysts at LADENBURG THALM/SH SH from $104.00 to $122.00 in a research note issued on Thursday, The Fly reports. LADENBURG THALM/SH SH’s price target points to a potential upside of 23.44% from the stock’s current price. Several other analysts also recently weighed […]
Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month price objective […]